Bristol-Myers Squibb Announces Time Change for Q4 Earnings Results Conference Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BMO Capital Reiterates Outperform on Bristol-Myers Squibb (BMY)
January 25, 2019 8:45 AM ESTBMO Capital analyst, Alex Arfaei, reiterated an Outperform rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) following the company's 4Q earnings report. Arfaei remains comfortable with Bristol's independent business: from 2018 to 2022, BMO Capital forecasts revenue and EPS CAGRs of 5% and 8%,... More
